Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Shares Outstanding (Weighted Average) (2016 - 2025)

Altimmune (ALT) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $88.1 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 24.08% to $88.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $88.1 million through Dec 2025, up 24.08% year-over-year, with the annual reading at $88.1 million for FY2025, N/A changed from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $88.1 million at Altimmune, up from $82.2 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $88.1 million in Q4 2025, with the low at $1.0 million in Q2 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $43.4 million, with a median of $50.4 million recorded in 2023.
  • Peak annual rise in Shares Outstanding (Weighted Average) hit 195406.41% in 2021, while the deepest fall reached 87.41% in 2021.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $2.8 million in 2021, then skyrocketed by 1590.31% to $46.9 million in 2022, then grew by 13.47% to $53.2 million in 2023, then skyrocketed by 33.35% to $71.0 million in 2024, then increased by 24.08% to $88.1 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $88.1 million, $82.2 million, and $81.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.